Skye Bioscience licenses Halozyme's ENHANZE technology for subcutaneous nimacimab

Skye Bioscience, Inc.

Non-exclusive license to Halozyme's ENHANZE drug delivery tech for subcutaneous nimacimab formulation.
Halozyme to be exclusive supplier of clinical and commercial rHuPH20 API for the product.
Milestone payments tied to development, commercialization, and net sales levels; mid-single digit royalties on worldwide net sales.
Agreement includes customary termination rights, reps, warranties, and indemnification.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.